Table 6.

Estimated true number of cases and prevalence, by stage, project and overall

Project	Estimated number of cases (95% confidence interval)			Prevalence in% (95% confidence interval)
	Observed	True cases among observed	True cases overall	Observed†	True‡
Kiri
stage 1	114	135, 143 (127–158)	177, 315 (255–388)	0.23	0.31, 0.56 (0.45-0.69)
stage 2	107	86, 71 (55–86)	86, 189 (145–257)	0.22	0.15, 0.33 (0.26-0.45)
Total	221	221, 214 (207–219)	263, 507 (429–608)	0.45	0.46, 0.90 (0.76-1.07)
Adjumani
stage 1	692	868, 913 (863–963)	1129, 1628 (1485–1775)	0.44	0.38, 0.54 (0.49-0.59)
stage 2	727	551, 463 (410–513)	648, 993 (872–1128)	0.46	0.22, 0.33 (0.29-0.38)
Total	1419	1419, 1375 (1360–1389)	1777, 2618 (2436–2811)	0.90	0.59, 0.87 (0.81-0.94)
Arua-Yumbe
stage 1	327	404, 392 (366–417)	495, 624 (564–693)	0.12	0.14, 0.17 (0.15-0.19)
stage 2	243	166, 135 (109–162)	153, 262 (214–321)	0.09	0.04, 0.07 (0.06-0.09)
Total	570	570, 527 (510–540)	648, 888 (816–974)	0.21	0.18, 0.24 (0.22-0.27)

†Observed cases divided by the total population actually screened. ‡Estimated cases divided by the total population targeted for screening.

Estimated figures indicate, respectively, sum of best-fitting values for each screening session, median of bootstrapping replicate samples (95% percentile of bootstrapping samples).